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S U M M A R Y
Background: In a previous study covering the period 1998–2004, we estimated the incidence of invasive
pneumococcal disease (IPD) in Singapore to be 13.6 per 105 children aged <5 years, and determined that
the 7-valent pneumococcal conjugate vaccine (PCV-7) would provide 78.1% serotype coverage for
children aged <5 years. In the present study we sought to determine whether incidence and serotype
trends have changed and to estimate pneumococcal vaccine coverage.
Methods: We retrospectively reviewed IPD cases from 2005 to 2010 and calculated separate serotype
proportions and population-based incidence rates for 2005–2007 (early PCV period) and 2008–2010
(late PCV period). PCV-7 coverage was obtained from the National Immunisation Registry, and patients
with PCV-7 vaccine-type IPD (VT IPD) and non-vaccine-type IPD (non-VT IPD) were compared.
Results: One hundred and eighteen patients, with a mean age of 46 months, were identiﬁed during
2005–2010. The incidence rate of IPD increased to 14.8 (for 2005–2007) and 15.2 (for 2008–2010) per
105 children <5 years, despite a gradual increase in PCV-7 coverage to approximately 45% of the birth
cohort receiving one or more doses of PCV-7. Although IPD due to serotypes 6B and 19A increased, there
was a concomitant reduction in other serotypes. Coverage by PCV-7 progressively declined from 78.6% in
2005–2007 to 64.4% in 2008–2010 for children aged <5 years.
Conclusions: Although population coverage with PCV-7 has risen, it remains suboptimal and the
incidence of IPD remains unchanged. Furthermore, signiﬁcant serotype changes (especially increases in
19A) have occurred. We need to adopt newer PCVs with broader serotype coverage and increase the
number of children vaccinated as a matter of urgency.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Streptococcus pneumoniae is the most common cause of vaccine-
preventable deaths in children aged <5 years worldwide.1 In
Singapore, the Communicable Diseases Division of the Ministry of
Health recently reported that S. pneumoniae resulted in a mean
annual hospitalization rate over 10 years of >80 per 105 children
aged <15 years.2 However, as the study was based on discharge
diagnoses, it was unclear if all cases were microbiologically
conﬁrmed. In a previous study covering the period 1998–2004, we
estimated the incidence of laboratory-conﬁrmed invasive pneu-
mococcal disease (IPD) at 13.6 per 105 children aged <5 years, and
that the 7-valent pneumococcal conjugate vaccine (PCV-7 or§ This paper was presented in part as an oral presentation at the 12th Western
Paciﬁc Congress on Chemotherapy and Infectious Diseases, Singapore, December 2–
5, 2010, under the title ‘‘Impact of conjugate pneumococcal vaccine coverage and
invasive pneumococcal disease incidence in Singapore children’’.
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1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.11.014Prevenar1) would cover 78.1% of IPD isolates in children <5 years
old.3 However, despite being licensed locally since 2002, the
vaccine was unavailable until 2005. From 2005 to 2009, vaccine
uptake gradually increased, but it was believed that most of the
vaccinated children were in the private sector. Singapore decided
to include PCV-7 in the National Childhood Immunisation Program
(NCIP) in October 2009, adopting a reduced-dosing schedule
similar to that used in the UK: administering ‘2 + 1’ doses to
children starting at <1 year old, and a single dose to children aged
between 1 and 5 years.4
With the inclusion of PCV-7 into the NCIP, it was anticipated
that large-scale infant and catch-up vaccination might occur.
However, for a variety of reasons relating to the mechanism of
funding of the NCIP, the uptake of PCV-7 may not have been as high
as anticipated. In addition, we noted inpatient admissions of
children with IPD who had previously been vaccinated with the
PCV-7, suggesting either vaccine failure or non-PCV-7 IPD (we did
not have access to the serotypes at the time of disease).
Hence, the current study aimed to compare two time-periods:
period 1, the years 1998–2004, pre-introduction of PCV-7; andses. Published by Elsevier Ltd. All rights reserved.
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after the inclusion of PCV-7 into the NCIP. Period 2 was further
separated into an early PCV period (2005–2007) and a late PCV
period (2008 to 2010). Incidence rates of IPD and the proportions of
pneumococcal serotypes causing IPD were compared between
these time periods. We also aimed to report the population PCV-7
coverage rates from the national vaccine notiﬁcation data (for
period 2) and to compare clinical and demographic characteristics
of patients with IPD due to PCV-7 serotypes (vaccine-type IPD, or
VT IPD) with those of patients with IPD due to non-PCV-7 serotypes
(non-vaccine-type IPD, or non-VT IPD) from period 2.
2. Materials and methods
2.1. Study design and data collection
KK Women’s and Children’s Hospital (KKH) is the largest
tertiary obstetric and pediatric hospital in Singapore. It has
approximately 350 pediatric beds, and sees approximately 54% of
all pediatric admissions nationally (based on market trends,
Corporate Communications, KKH). We retrospectively identiﬁed
all children <16 years of age admitted from January 2005 through
December 2010 with laboratory-conﬁrmed IPD from microbiology
records, and reviewed their case-notes. The current study period
was designated period 2, which was further subdivided into the
‘early PCV introduction period’ from 2005 to 2007 due to the post-
hoc analysis showing population PCV coverage to be <40% prior to
2008, and a ‘late PCV introduction period’ when PCV coverage was
>40%, from 2008 onwards; the previous study period (1998–2004)
was designated period 1.3
The following data were collected: demographics; vaccination
status; immunocompetence status (as deﬁned by absence of
congenital or acquired immunodeﬁciencies or conditions, or
receipt of immunosuppressive medications); clinical syndrome,
level of care, need for invasive procedures, length of stay, and ﬁnal
outcome; pneumococcal serotype; and antibiotic susceptibility
patterns.
Serotyping was performed by Quellung reaction using pneu-
mococcal antisera (Statens Serum Institut, Copenhagen, Denmark).
Antibiotic susceptibility testing was performed using disk diffu-
sion by calibrated dichotomous sensitivity (CDS) method.5 In
addition, penicillin and ceftriaxone minimum inhibitory concen-
trations (MIC) were determined by the E-test (AB Biodisk, Sweden).
Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS)
breakpoints (M100-S14) were used to categorize the MIC results
obtained for penicillin, amoxicillin, and ceftriaxone (non-menin-
gitis breakpoints for amoxicillin and ceftriaxone, but meningitis
breakpoints for penicillin), while CDS breakpoints were used to
characterize results obtained for erythromycin and trimethoprim–
sulfamethoxazole (TMP–SMX).6
2.2. Case deﬁnitions
Laboratory-conﬁrmed IPD was deﬁned as the isolation of viable
pneumococci from blood, cerebrospinal ﬂuid (CSF), pleural or
peritoneal ﬂuid, or other normally sterile sites such as bone and
joints. Invasive clinical syndromes were deﬁned as follows: (1)
bacteremia: presence of viable bacteria in the blood in the absence
of a focus of infection; (2) pneumonia: lung infection with fever/
hypothermia and cough, supported by radiographic evidence of
new-onset pulmonary inﬁltrates or consolidation, together with
the isolation of viable bacteria either from the blood or pleural
cavity or lung tissue; this was further characterized according to
whether or not patients had concomitant pleural effusion/
empyema, as deﬁned by the presence of ﬂuid or pus in the pleural
cavity; (3) meningitis: inﬂammation of the cerebral meningessecondary to pneumococcal infection, as conﬁrmed by growth on
CSF cultures, or positive pneumococcal-speciﬁc latex agglutination
test on CSF with concomitant bacteremia; presence of CSF
pleocytosis or leptomeningeal enhancement/subdural collections
without positive CSF cultures or latex agglutination but with
concomitant bacteremia were also included; (4) other deep-seated
infections: presence of viable bacteria at a normally sterile site
such as joint ﬂuid, etc.
Clinical criteria for the performance of blood cultures for
pediatric inpatients at KKH include any need for intravenous
antibiotics and on the basis of any clinical suspicion for septicemia
(usually without exception, though occasionally they may be
performed after the receipt of intravenous antibiotics). Lumbar
punctures for CSF collection are routinely performed on the basis of
clinical suspicion for meningitis, with rare exceptions in situations
where there is signiﬁcant cardio-respiratory instability or where
there is a signiﬁcant risk of bleeding or raised intracranial pressure.
There were no known changes in clinical practice for the above two
procedures during the two study periods.
2.3. Estimation of IPD incidence
Annual incidence rates of IPD in Singapore children from 2005
to 2010 (deﬁned as period 2) were estimated using a previously
described method and were compared to the previous study period
(1998–2004; period 1).3 Brieﬂy, the incidence rate (per 105
children in the age bracket) = (number of IPD cases in the age
bracket at KKH)  (100/54)  (100 000/N), where N represents the
number of children in that age bracket living in Singapore for that
particular year (derived from Singapore Department of Statistics
data).7,8 This calculation was based on the following assumptions:
(1) that all IPD cases in Singapore children were admitted to a
hospital; and (2) that KKH admitted 54% of all pediatric inpatients
in Singapore. The incidence rate for period 1 was compared with
the early and late PCV introduction periods within period 2.
2.4. Estimation of national pneumococcal vaccine coverage
Estimates of pneumococcal vaccine coverage were obtained by
extracting data from the National Immunisation Registry (NIR),
which was established in 2003 by the Health Promotion Board
(HPB) to collect and maintain vaccination records of children from
birth to 18 years of age; notiﬁcation of immunisation by healthcare
professionals in Singapore to the NIR is required by law, with
notiﬁcations generally exceeding 95% of the birth cohort.9
Speciﬁcally, we extracted the number of children who received
PCV-7, the age at ﬁrst dose, and the number of doses received, and
calculated vaccine coverage as the proportion of the birth cohort
vaccinated with at least one dose of PCV-7, yearly from 2005
through 2010.7
2.5. Statistical analysis and approval
Descriptive statistics were applied to continuous data, and non-
parametric (Mann–Whitney) tests were performed to look for
differences in age and length of stay. Incidence rates were
compared between different populations and time-periods using
OpenEpi software, v2.3.1.10 Two-tailed Chi-square analyses (or
Fisher’s exact test, for data with values <5) were performed to look
for statistically signiﬁcant differences in patient demographics,
vaccination status, immunocompetence, clinical characteristics,
outcome, serotype, and serotype changes. Stepwise multivariate
logistic regression was performed on independent variables to
assess their effects on the development of VT vs. non-VT IPD. p-
Values were considered signiﬁcant at <0.05. Data analysis was
performed using SPSS for Windows v.12 (Chicago, IL, USA).
Figure 1. Distribution of invasive pneumococcal disease cases classiﬁed by clinical syndrome, age group, and period.
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approval was also obtained from the HPB for extraction of
pneumococcal vaccination data from the NIR.
3. Results
3.1. Demographics and distribution of patients by site of infection
A total of 118 patients with 122 episodes of IPD were identiﬁed
for the period 2005 to 2010. Three patients had repeated infections,
all of whom had an underlying immunodeﬁciency (hyper IgE
syndrome, nephrotic syndrome, and chronic infantile neurological,
cutaneous and articular (CINCA) syndrome); only the ﬁrst episode
for each of these patients was included in the analysis. The median
patient age was 46 months (interquartile range (IQR) 27–57
months), which was signiﬁcantly different from the median age in
period 1 of 37 months (IQR 24–60 months) (p < 0.0001). Seventy-
three of the 118 patients were male (61.9%). In terms of racial
composition, 53.4% (n = 63) of the patients were Chinese, 28.8%Figure 2. Trends in incidence of invasive pneumoco(n = 34) were Malay, 11.9% (n = 14) were Indian, and 5.9% (n = 7)
were of other racial descent; this was signiﬁcantly different from
the racial composition of Singapore (74.1% Chinese, 13.3% Malay,
9.2% Indian, and 3.3% ‘others’) (p = 0.01). There were 87 cases of
invasive pneumococcal pneumonia (73.7%), 14 cases of bacteremia
(11.9%), eight cases of meningitis (6.8%), and nine cases who had
infections involving other sterile sites (7.6%); these ﬁgures were
not statistically different from the previous period (period 1),
although there were fewer cases of bacteremia and meningitis and
more cases of other deep-seated infections. Figure 1 shows the
distribution of cases comparing study periods 1 and 2, further
subdivided by age group.
3.2. Estimates of incidence rates compared with vaccine coverage
rates
Figure 2 shows the trends in the estimated IPD incidence rates
for the two time-periods. The incidence rate of IPD per 105 children
aged <5 years in the early PCV introduction period was 14.8, whichccal disease classiﬁed by age group and period.
Table 1
Changes in proportion of IPD serotypes from period 1 to period 2 (period 2 further divided into ‘early’ and ‘late’ PCV introduction periods)
Serotype Period 1, n (%) Period 2, n (%)
‘Early’ (2005–2007) ‘Late’ (2008–2010)
14 32 (34.8%) 21 (30%) 9 (20%)
6B 15 (16.3%) 21 (30%) 12 (26.7%)
23F 15 (16.3%) 4 (5.7%) 6 (13.3%)
19F 8 (8.7%) 9 (12.9%) 2 (4.4%)
6A 5 (5.4%) 3 (4.3%) 2 (4.4%)
19A 3 (3.3%) 8 (11.4%) 12 (26.7%)
‘Others’a 14 (15.2%) 4 (5.7%) 2 (4.4%)
IPD, invasive pneumococcal disease; PCV, pneumococcal conjugate vaccine.
a Other less frequently detected serotypes include serotypes 1, 3, 9, 15, 18 (not further typed), 23A, and 33.
Figure 3. Trends in invasive pneumococcal disease from 2001 to 2010.
K.C. Thoon et al. / International Journal of Infectious Diseases 16 (2012) e209–e215e212did not differ signiﬁcantly from that of 13.6 in period 1 (incidence
rate ratio (IRR) 1.093, 95% conﬁdence interval (95% CI) 0.852–
1.403; incidence rate difference (IRD) 0.126, 95% CI 0.235–0.487;
p = 0.49). There was also no statistical difference in incidence rate
of IPD in the late PCV introduction period (15.2) compared with
period 1 (IRR 1.121, 95% CI 0.875–1.436; IRD 0.164, 95% CI 0.201–
0.529; p = 0.37), or with the early PCV period. However, the IPD
incidence rate for children aged 2–5 years was signiﬁcantly greater
in both the early and late PCV introduction periods (equal
incidence rates in each sub-period, 18 per 105 children) compared
with period 1 (11.3 per 105 children; IRR 1.599, 95% CI 1.182–
2.163; IRD 0.679, 95% CI 0.197–1.16; p = 0.003). The incidence rate
for IPD in children aged <2 years was also signiﬁcantly lower in the
early PCV period compared with period 1 (9.5 per 105 children
compared with 16.9, IRR 0.556, 95% CI 0.344–0.9; IRD 0.747, 95%
CI 1.276 to 0.218; p = 0.01), as well as the late PCV period
compared with period 1 (10.4 per 105 children compared with
16.9, IRR 0.612, 95% CI 0.385–0.972; IRD 0.654, 95% CI 1.198 to
0.109; p = 0.03).
Data extracted from the NIR revealed that while PCV-7 uptake
was poor in its ﬁrst year of availability in 2005 (19.4% of birth
cohort receiving at least one dose of PCV, with 76.7% receiving it
after the age of 1 year, and 57.8% receiving only one dose of PCV), it
progressively increased to 28.8% in 2006 (60.5% vaccinated after 1
year, 45.3% receiving only one dose), 36.1% in 2007 (50% vaccinated
after 1 year, 35.9% receiving only one dose), 46.6% in 2008 (54.2%
vaccinated after 1 year, 45.1% receiving only one dose), and 45.5%
in 2009 (17.7% vaccinated after 1 year, 26.3% receiving only one
dose; this was the year PCV was included in our NCIP). However, it
should be noted that more than half of the vaccinated childrenreceived only one or two doses of PCV-7, and prior to 2009 more
than half were vaccinated after 1 year of age, reﬂecting either
incomplete or delayed age of vaccination.
3.3. Changes in composition of IPD serotypes
Of 118 cases of IPD in period 2, 115 isolates were available for
serotyping, and we compared these to isolates serotyped in period
1 (see Table 1 and Figure 3). There was a signiﬁcant difference in
serotype composition between period 1 and both the early
(p = 0.01) and late PCV introduction periods (p < 0.001), but
changes between the early and late PCV period did not achieve
statistical signiﬁcance (p = 0.19). Serotype 6B increased from 16.3%
to 28.7% (for period 2 as a whole) and serotype 19A increased by
more than 5-fold from 3.3% to 17.4% (again for period 2 as a whole,
though it contributed 26.7% to IPD between 2008 and 2010). It
should be noted that this increase was small in absolute terms
(only 10 isolates in 2010). The increase in 19A occurred in 2004
even before PCV-7 was made available locally, but became more
pronounced in 2010, during the ﬁrst year of introduction of PCV-7
into the NCIP. However, IPD due to serotypes 14 and 23F decreased
signiﬁcantly, together with other less common serotypes. Serotype
19F increased slightly from period 1 to the early PCV period then
decreased, while serotype 6A remained fairly constant. Hence,
while the proportion of IPD serotypes covered by PCV-7 during
period 2 was not signiﬁcantly different from period 1 (73% vs.
75.3%, or 75.8% vs. 78.1% in children <5 years), the coverage was
78.6% in the early PCV introduction period and decreased to 64.4%
in the late PCV period. Also, while the newer PCV-10 could
increase coverage marginally and may be expected to provide
Table 2
Comparison of clinical characteristics between patients with vaccine-type vs. non-vaccine-type disease
Patient characteristics VT IPD (n = 84) Non-VT IPD (n = 31) Univariate p-value Multivariate p-value
Age, months, median (IQR) 42 (24–54) 52 (40–68) 0.03a 0.07
Sex, male, n (%) 55 (65.5%) 17 (54.8%) 0.29 NA
Race, n (%)
Chinese 40 (47.6%) 22 (71.0%) 0.03a 0.69
Malay 31 (36.9%) 2 (6.5%) 0.001a 0.02a
Indian 9 (10.7%) 4 (12.9%) 0.75 NA
Other 4 (4.8%) 3 (9.7%) 0.39 NA
Previous receipt of PCV, n (%) 0.001a 0.001a
None 83 (98.8%) 25 (80.6%)
Incomplete 0 1 (3.2%)
Complete 1 (1.2%) 5 (16.1%)
Immunocompetent, n (%) 76 (90.5%) 26 (83.9%) 0.32 NA
Site of infection, n (%) 0.41 NA
Pneumonia 58 (69.0%) 26 (83.9%)
Meningitis 7 (8.3%) 1 (3.2%)
Bacteremia 11 (13.1%) 3 (9.7%)
Other 8 (9.5%) 1 (3.2%)
Required chest-tube insertion or thoracoscopic surgery,
only in patients with pneumonia, n (%)
15 of 58 (25.9%) 16 of 26 (61.5%) 0.001a 0.001a
Proportion of isolates non-susceptible to penicillins, n (%) 48 (57.1%) 17 (54.8%) 0.84 NA
Proportion of isolates non-susceptible to cephalosporins
(not all tested), n of N, where N = number of isolates tested (%)
8 of 64 (12.5%) 10 of 28 (35.7%) 0.02a NA
Proportion of isolates non-susceptible to erythromycin, n (%) 74 (88.1%) 21 (67.7%) 0.03a NA
Proportion of isolates non-susceptible to trimethoprim–
sulfamethoxazole, n (%)
63 (75%) 25 (80.6%) 0.63 NA
Length of stay, days, median (IQR) 8 (6–14) 15 (7–18) 0.04a 0.3
Required intensive care, n (%) 17 (20.2%) 11 (35.5%) 0.09 0.68
Required high dependency care, n (%) 26 (31.0%) 15 (48.4%) 0.08 0.42
Outcome, n (%)
Alive without sequelae 76 (90.5%) 28 (90.3%)
Alive with sequelae 5 (5.9%) 2 (6.5%) 0.98 NA
Dead 3 (3.6%) 1 (3.2%)
VT, vaccine-type; IPD, invasive pneumococcal disease; IQR, interquartile range; NA, not applicable (not entered into regression analysis); PCV, pneumococcal conjugate
vaccine.
a p-Value is signiﬁcant.
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serotypes in children aged <5 years in period 2), the use of PCV-13
could increase coverage to 96.7% of IPD serotypes in children aged
<5 years for period 2.
3.4. Comparison of clinical characteristics between patients with VT
vs. non-VT IPD
Table 2 lists the characteristics of patients with available
serotyping data, classiﬁed by VT vs. non-VT serotypes; 20 of the 31
non-VT IPD cases were due to serotype 19A (64.5%). There were no
signiﬁcant differences between the two groups in terms of sex,
immunocompetence, and site of infection. Patients who developed
non-VT IPD were 10 months older than those who developed VT-
IPD (median 52 vs. 42 months of age, p = 0.03), although this
association was non-signiﬁcant on multivariate analysis. Malay
patients were more likely to develop VT IPD (odds ratio (OR) 8.47,
95% CI 1.89–38.46), while the Chinese were more likely to develop
non-VT IPD (OR 2.69, 95% CI 1.11–6.52); the association for the
Chinese became non-signiﬁcant on multivariate analysis, but
remained signiﬁcant for the Malays (p = 0.02). Patients with non-
VT IPD were signiﬁcantly more likely to have received at least 1
dose of PCV-7 (OR 19.9, 95% CI 2.29–173.37; p = 0.001); this
difference persisted after multivariate analysis (p = 0.001). When
analyzed separately, patients with 19A IPD were even more likely
to have received any dose of vaccine (OR 40.29, 95% CI 4.51–
360.03; p < 0.0001). (Note: the majority of non-VT patients (80.6%)
were unvaccinated.)
With regard to clinical burden, while patients with non-VT IPD
were more likely to require treatment in intensive care (35.5% vs.
20.2%) or high dependency units (48.4% vs. 31.0%), these did not
reach statistical signiﬁcance. There were also no signiﬁcantdifferences in ﬁnal outcome. However, patients with non-VT IPD
had a signiﬁcantly longer length of stay (median 15 days)
compared with patients with VT-IPD (median 8 days, p = 0.04),
but this difference became non-signiﬁcant after multivariate
analysis. For IPD patients with pneumonia, 36.9% (31 of 84)
required thoracoscopic surgery or chest-tube insertion (an indirect
marker for complicated pneumonia); of these, 15 (48.4%) were due
to VT and 16 (51.6%) to non-VT isolates. The serotype distribution
of pneumococcal isolates causing complicated pneumonia was as
follows: seven were serotype 6B isolates, six were serotype 14
isolates, and two were serotype 19F isolates (for 15 VT isolates);
one was serotype 3, two were serotype 6A, and 13 were serotype
19A isolates (for 16 non-VT isolates). Patients with non-VT
pneumonia were more likely to have complicated pneumonia
(OR 4.59, 95% CI 1.74–12.13). For patients with serotype 19A
pneumonia, the risk of complications increased further (to OR of
6.96, 95% CI 2.46–19.76).
In terms of susceptibility patterns, there were no signiﬁcant
differences between VT and non-VT IPD with regards to penicillin
and TMP–SMX susceptibility. However, non-VT isolates (compared
with VT isolates) were slightly more susceptible to erythromycin
(67.7% vs. 88.1%), but were much less susceptible to ceftriaxone
(35.7% non-susceptibility vs. 12.5%, where tested). None of the
isolates were penicillin- or ceftriaxone-resistant according to the
latest CLSI non-meningitis guidelines. All 10 non-VT isolates that
were ceftriaxone-non-susceptible were serotype 19A.
4. Discussion
Suboptimal PCV-7 vaccine coverage from 2005 has not yet
impacted overall IPD incidence rates. Similar results have
been seen in other countries where vaccine uptake is also
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countries following the introduction of PCV-7 into universal infant
vaccination programs, whether according to manufacturer-recom-
mended or reduced-dosing schedules.13–18 It is uncertain what
proportion of our population needs to be vaccinated in order to
make an impact on IPD incidence rates, but lessons learned from
the USA during the years of IPD decline despite vaccine shortage
suggest that the herd immunity threshold might be around 63–
85%.19 Furthermore, there is evidence that both direct and indirect
herd beneﬁts can be seen even when children receive fewer than
the recommended number of doses of vaccine, although the
minimum seems to be at least two doses.20,21 We also found that
the age distribution of IPD has shifted upwards, with fewer
children aged <2 years developing IPD compared to the 2–5 years
age group. A possible explanation for this would be that in the
absence of a national recommendation for catch-up vaccination for
children aged 2–5 years, more children aged <2 years were
vaccinated compared with older children. However, this would not
explain the increased burden of IPD in the 2–5 years age group, and
whether or not this relates to the serotype changes that were found
remains uncertain.
Despite increasing vaccine coverage, the serotype coverage of
PCV-7 did not change much despite signiﬁcant changes in serotype
compositions between the two study periods, with an increased
contribution from serotypes 6B and 19A, though the coverage did
decrease in the late PCV introduction period. Serotype replacement
in IPD is a complex phenomenon that appears to be near universal,
although the explanation for this is unclear and seems dependent
on geography, vaccine coverage, and local antimicrobial prescrib-
ing practices.12,17,18,22–28 Heptavalent pneumococcal conjugate
vaccines have been shown to be capable of reducing nasopharyn-
geal carriage of VT pneumococci and can theoretically account for
some of the serotype replacement phenomena.29,30 However, this
cannot be the sole explanation, since (as our data have also shown)
in many countries the incidence of non-VT pneumococci such as
serotype 19A were ﬂuctuating and had increased prior to the
introduction of PCV into their universal vaccination programs.
Clonal expansion of non-VT serotypes (whether pre-existing or
newly-introduced into the community) that have greater ecologi-
cal ‘ﬁtness’ compared to existing serotypes could also explain
serotype replacement.23,27–31 Alternatively, antimicrobial pressure
(particularly with macrolides like azithromycin) has been postu-
lated as being important in altering nasopharyngeal carriage of
pneumococcal serotypes, selecting for less susceptible serotypes
including 19A.32,33 Finally, pneumococci may undergo capsular
switching from VT to non-VT serotypes as a ‘survival’ mechanism
to avoid elimination after multiple pressures.30 The small size of
our study population does not permit us to draw ﬁrm conclusions
regarding the deﬁnite mechanisms underlying the changes that we
see, although we hypothesize that sufﬁcient antibiotic and vaccine
pressure could have selected for more ‘ﬁt’ serotypes in our local
context.
During period 2, we found that those of Malay race were
signiﬁcantly more likely to develop VT IPD, while receipt of any
dose of PCV-7 in any racial group was strongly associated with the
development of non-VT IPD; patients with non-VT IPD were also a
year older (although not signiﬁcantly so after multivariate
analysis). While differences in genetic susceptibility to different
invasive pneumococcal serotypes may be possible, most studies
have found that the use of PCV has either abolished or narrowed
the racial differences in rates of IPD in children.13,18,34 Also, Malays
in Singapore have a lower median monthly income compared to
those of other races, and the above racial differences could possibly
be due to them being much less likely to be vaccinated with PCV-7;
however we do not have population coverage data divided by
ethnicity to conﬁrm this.35 The development of non-VT IPD afterPCV-7, should it occur, likely represents breakthrough infection,
and was reassuring as it would suggest that there was no vaccine
failure. Furthermore, we did not show that the absolute risk of
developing IPD in vaccinated children was greater than in
unvaccinated children, but rather should vaccinated children
develop IPD, it would more likely be due to non-VT serotypes.
The overall penicillin non-susceptibility rates increased from
44% in period 1 (results published in an earlier study by Chong
et al.) to 56.5% in the current study period, while overall
ceftriaxone non-susceptibility increased from 15% in period 1 to
19.6% in period 2.3 The increase in penicillin non-susceptibility
appears to be uniformly distributed amongst VT and non-VT
isolates, but ceftriaxone non-susceptibility is signiﬁcantly more
frequent in non-VT isolates, with 19A being the sole contributor in
our series. In a recent review of the burden of IPD in children from
the Asia-Paciﬁc, penicillin non-susceptibility in invasive pneumo-
coccal isolates increased in nearly all countries where updated
ﬁgures were available (65% in 2007 in Hong Kong, 86% in 2008 in
Japan, and up to 86% in 2009 in Taiwan); our ﬁgures parallel the
increases regionally, but at a more moderate pace, and this likely
reﬂects the regional increase in antimicrobial usage.36 Taiwan also
had the highest rates of ceftriaxone non-susceptibility (at 8–21%
for non-meningitis cases and 56–76% for meningitis cases) in the
region, and although most of the non-susceptible isolates were VT
(14, 19F and 23F), serotype 19A had also expanded, with high non-
susceptibility rates.26,36 The increase in broadly drug-resistant
serotype 19A pneumococci has been well described and, together
with traditionally resistant VT pneumococci, could lead to increased
rates of clinical morbidity with increased treatment failures and
medical costs.25 Universal PCV-7 vaccination has been shown to
signiﬁcantly reduce pneumococcal resistance rates in VT serotypes
(primarily through a herd effect) and hopefully the ‘next-generation’
PCVs that protect against non-VT isolates will also achieve this.37
Rates of complicated pneumonia remained stable between
period 1 (39%, as previously published by Chong et al.) and period 2
(36.9%).3 However, in the current study period, we noted that more
patients with non-VT pneumonia developed effusions or empy-
emas requiring chest tube insertion or thoracoscopic surgery, with
serotype 19A contributing 41.9% of all complicated pneumonia.
Several of the non-PCV-7 serotypes (in particular serotypes 1, 5,
and 19A) have been implicated in the increase in complicated
pneumonia, and some investigators have suggested that the
introduction of PCV-7 may have caused this (again through the
theory of serotype replacement).38–40 However, our data do not
suggest any absolute increase in numbers of complicated
pneumonia, but rather that most of it has been replaced by
non-PCV-7 serotypes; this may be due to increased virulence in the
non-PCV-7 serotypes.41 This is of concern in our context, since the
clinical burden now appears to be in children who may have been
vaccinated with PCV-7, ironically with the original intention of
decreasing their risk of invasive disease. Again, we hope that the
use of ‘next-generation’ PCVs will lead to a reduction in
complicated pneumonia.
There are several limitations to our study. First, the ecological
nature did not permit deﬁnite conclusions to be drawn with
regards to cause-and-effect between vaccine coverage, IPD
incidence, and serotype changes. We intend to try and resolve
part of the question by determining whether clonal expansion of
19A could have occurred locally. Second, our incidence rate
estimates could be erroneous since KKH’s market share of
hospitalized children is only an assumption. Third, our estimates
of population PCV-7 coverage may be inaccurate as this depends on
passive reporting by healthcare providers to the NIR. Fourth, as our
numbers were relatively small, serotype proportions and incidence
trends could be signiﬁcantly distorted by small changes in the
numbers of isolates. Finally, as mentioned above, when comparing
K.C. Thoon et al. / International Journal of Infectious Diseases 16 (2012) e209–e215 e215patients with VT vs. non-VT IPD, we did not show that the absolute
risk of developing IPD in vaccinated children was greater than in
unvaccinated children; however, we intend to address this
question by performing longitudinal studies looking at absolute
risks of IPD in vaccinated and unvaccinated children in Singapore.
In conclusion, despite the above limitations, we see that while
progressive increases in PCV-7 vaccine coverage have occurred, the
overall incidence of IPD has remained unchanged. Also, serotype
changes have occurred that may now limit the utility of the ‘older’
PCVs, although the proportion of serotype coverage remains good.
Hence, we believe that while the arrival of ‘next-generation’ PCVs
with broader serotype coverage would be greatly welcomed and
are much needed, it is equally important to broaden the population
PCV coverage as quickly as possible. We need to continue
surveillance for further serotype changes and to assess the impact
of universal vaccination with pneumococcal conjugate vaccines.
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